Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
16.71
-0.39 (-2.28%)
At close: Mar 12, 2026, 4:00 PM EDT
16.46
-0.25 (-1.50%)
After-hours: Mar 12, 2026, 7:45 PM EDT
Avalo Therapeutics Employees
Avalo Therapeutics had 23 employees as of December 31, 2024. The number of employees increased by 4 or 21.05% compared to the previous year.
Employees
23
Change (1Y)
4
Growth (1Y)
21.05%
Revenue / Employee
$8,348
Profits / Employee
-$4,334,826
Market Cap
309.35M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2024 | 23 | 4 | 21.05% | 23 | 0 |
| Dec 31, 2023 | 19 | -1 | -5.00% | 19 | 0 |
| Dec 31, 2022 | 20 | -24 | -54.55% | 20 | 0 |
| Dec 31, 2021 | 44 | 13 | 41.94% | 42 | 2 |
| Dec 31, 2020 | 31 | 13 | 72.22% | 30 | 1 |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Puma Biotechnology | 179 |
| AC Immune | 172 |
| Cabaletta Bio | 151 |
| Nautilus Biotechnology | 130 |
| Adlai Nortye | 123 |
| Foghorn Therapeutics | 112 |
| C4 Therapeutics | 110 |
| Camp4 Therapeutics | 55 |
AVTX News
- 16 days ago - Avalo Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 22 days ago - Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Avalo Therapeutics Stock Has More Than 200% Upside? Analyst Breaks Down Bull And Bear Case - Benzinga
- 4 months ago - Avalo Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates - GlobeNewsWire
- 4 months ago - Avalo Therapeutics Announces Completion of Enrollment in Phase 2 LOTUS Trial of AVTX-009 for the Treatment of Hidradenitis Suppurativa - GlobeNewsWire
- 5 months ago - Avalo Therapeutics Expands Leadership Team with Key Appointments in Business Development and Human Resources - GlobeNewsWire
- 6 months ago - Avalo Therapeutics Appoints Kevin R. Lind to Board of Directors - GlobeNewsWire
- 7 months ago - Avalo Therapeutics: Speculative Buy Ahead Of AVTX-009's LOTUS Results - Seeking Alpha